Daily Stock Analysis, ADMS, Adamas Pharmaceuticals Inc, priceseries

Adamas Pharmaceuticals Inc. Daily Stock Analysis
Stock Information
Open
34.29
Close
33.77
High
34.72
Low
33.57
Previous Close
34.43
Daily Price Gain
-0.66
YTD High
44.00
YTD High Date
Jan 24, 2018
YTD Low
30.92
YTD Low Date
Feb 9, 2018
YTD Price Change
-1.88
YTD Gain
-5.27%
52 Week High
44.00
52 Week High Date
Jan 24, 2018
52 Week Low
13.50
52 Week Low Date
Aug 16, 2017
52 Week Price Change
16.49
52 Week Gain
95.43%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Nov 16. 2017
27.69
Dec 12. 2017
35.37
19 Trading Days
27.75%
Link
LONG
Jan 16. 2018
35.74
Jan 30. 2018
38.46
10 Trading Days
7.60%
Link
Company Information
Stock Symbol
ADMS
Exchange
NasdaqGM
Company URL
http://www.adamaspharma.com
Company Phone
510-450-3554
CEO
Gregory T. Went
Headquarters
California
Business Address
1900 POWELL ST., SUITE 750, EMERYVILLE, CA 94608
Sector
Equity
Industry Category
Drugs
Industry Group
Drugs - Generic
CIK
0001328143
About

Adamas Pharmaceuticals, Inc. operates as a pharmaceutical company, which engages in discovering chrono-synchronous therapies. It involves in the development and commercialization of therapeutics targeting chronic disorders of the central nervous system. The company was founded by Gregory T. Went on November 15, 2000 and is headquartered in Emeryville, CA.

Description

Adamas Pharmaceuticals, Inc., a pharmaceutical company, discovers, develops, and sells chrono-synchronous therapies for chronic neurologic disorders. The company's product portfolio comprises ADS-5102, a chrono-synchronous amantadine therapy for the treatment of levodopa-induced dyskinesia in patients with Parkinson's disease. Its portfolio also comprises of Namzaric (memantine hydrochloride extended-release and donepezil hydrochloride) capsules; and Namenda XR (memantine hydrochloride) extended release capsules for the treatment of moderate to severe Alzheimer's disease. The company's products under development include ADS-4101, a chrono-synchronous lacosamide therapy that has completed first Phase I clinical study for the treatment of partial onset seizures in patients with epilepsy. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.